Close
Nordic 9Nordic 9

Adjuvant Capital (investor - Private Equity)

United States adjuvantcapital.com
See something wrong or missing? Let us know
Offices:New York

Adjuvant Capital is a life sciences investment firm focused on global health companies, which it backs with $10-$25 million investments.

Average round investment:47.95M USD
Average number per year:2.2
Distribution: 2023 (3)2022 (4)2021 (1)2020 (1)
Portfolio companies: Switzerland Memo TherapeuticsDenmark MinervaXSwitzerland LimmaTech See the entire list
Mostly invests in: Switzerland Switzerland (3) Health services (8)
See the entire list

Showing 3 of 9 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Adjuvant Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Adjuvant Capital

Name Criteria
Sweden Trill Impact
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark, United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
France AXA IM
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Denmark, United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Belgium Gimv
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Belgium
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Switzerland Pictet Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Luxembourg 3B Future Health Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Belgium Novalis Biotech
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Sweden Sound Bioventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
United States Data Collective (DCVC)
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark, United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United Kingdom Legal & General
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.8
  • Active last 12 months: Yes
United Kingdom Advent Life Sciences
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Top